Mice were fed high-fat diet (HFD) (60 kcal% fat, D12492, Research diets, USA) or a control diet indicated with LFD (low fat diet) (10 kcal% fat, D12450J, Research diets, USA) for a period of 16 weeks. After 12 weeks, the diet was supplemented with a 4 week infusion of either angiotensin II (AngII) (1 mg/kg/day; Bachem, Switzerland) or saline using osmotic minipumps (Alzet 1004, Durect corporation, USA). Pumps were combined with polyetheretherketone tubing (Alzet PEEK tubing 0002612, Durect corporation, USA) to allow magnetic resonance imaging (MRI). Placement of pumps was performed as described before 7 (link). In brief, mice were anesthetized and placed in the prone position on a heating pad. A subcutaneous pocket was created in the right flank for pump insertion. The experimental set-up is outlined in Figure S1 C .
Alzet 1004
Manufactured by Durect
Sourced in United States
The Alzet 1004 is a laboratory equipment product designed for controlled and continuous drug delivery in small laboratory animals. It functions as an osmotic pump, providing a reliable and consistent release rate of test substances over an extended period of time.
Automatically generated - may contain errors
Lab products found in correlation
D12492, by Research Diets (1 mentions)
Angii, by Bachem (1 mentions)
Smx 800, by Nikon (1 mentions)
Male apoe mice, by Jackson ImmunoResearch (1 mentions)
Mitotempo, by Merck Group (1 mentions)
Mouse recombinant leptin, by Thermo Fisher Scientific (1 mentions)
Alzet brain infusion kit 3, by Durect (1 mentions)
10 protocols using alzet 1004
1
Angiotensin II Infusion in Mice Fed High-Fat Diet
2
Angiotensin II-Induced Aortic Aneurysm Model
3
Mitigating Metabolic Dysfunction in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All procedures were performed in compliance with protocols approved by the University of Michigan Institutional Animal Care and Use Committee in accordance with NIH guidelines. All mice were purchased from Jackson Laboratory (Bar Harbor, ME). Male wild‐type, Sod2+/− (B6.129S7‐Sod2tm1Leb/J), Apoe−/− (B6.129P2‐Apoetm1Unc/J), and Apoe−/−/Sod2+/− mice were bred on the C57BL/6J background. Experimental mice were generated from breeding heterozygous mice, and genotypes were confirmed by polymerase chain reaction. Mice were housed in specific pathogen‐free rooms in ventilated cages at 22°C with 12‐hour light/dark cycles and free access to food and water. Animals (n=16 per group) were fed standard rodent chow for 1 (young) or 13 months (middle‐aged) and then switched to the Western diet (Harlan Teklad TD.88137; Envigo, Madison, WI) for 3 months.
Mice were treated with MitoTEMPO (Sigma‐Aldrich, St. Louis, MO) at 1500 μg/kg per day for 12 weeks as described previously.9 Briefly, at 13 months of age mice were randomly assigned to a MitoTEMPO or a vehicle treatment group (n=12). Microosmotic pumps (ALZET 1004; Durect, Cupertino, CA) were implanted subcutaneously under 2% inhaled isoflurane/O2 anesthesia. The pumps were replaced every 4 weeks. Mice were fed the Western diet for the duration of the experiment.
Mice were treated with MitoTEMPO (Sigma‐Aldrich, St. Louis, MO) at 1500 μg/kg per day for 12 weeks as described previously.
4
Tamsulosin Pretreatment for Abdominal Aortic Aneurysm
5
Osmotic Pump Implantation Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Osmotic pumps (ALZet 1004; DURECT Corporation, Cupertino, CA, USA) were sterile-filled with either PBS or dexamethasone–cyclodextran solution (Sigma-Aldrich, St. Louis, MO, USA) for a dose of 4 mg/kg/d for the average 30-g mouse. The pumps were then left in 0.9% normal saline at 37°C for 48 hours before implantation. On day 0, body weight and IOP measurements were taken and then used to randomize treatment groups. Animals were anesthetized using isoflurane in an induction chamber and maintained on a nose cone (2%–3% isoflurane, 1 L/min oxygen) for the implantation. Loss of consciousness was determined by breathing pattern and toe pinch. A dose of carprofen (Rimadyl; Zoeitis, Parsippany, NJ, USA) was provided before making the incision. When the animals were deeply anesthetized, the back of the neck was shaved and cleaned with alternating swabs of 70% isopropyl alcohol and betadine. A small incision was made with a pair of sterile surgical scissors in the shaved area. Using a pair of sterile hemostats, a small pocket was made by opening and closing the hemostat in the subcutaneous space. The prefilled mini pump was inserted into the pocket, and the incision site was closed with wound clips. The stapled area of the skin was cleaned with a cotton tip applicator, and betadine was applied. Mice were then placed back in their cages with a heating pad to recover.
6
Recombinant αKlotho Protein Therapy for CP-Induced Kidney Injury
7
Leptin Treatment in Diabetic Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
STZ-diabetic mice at 10 weeks of age received 20 μg/day of recombinant mouse leptin (Peprotech, Rocky Hill, NJ, USA) prepared in sterile water and administered via Alzet 1004 mini-osmotic pumps (DURECT Corporation, Cupertino, CA, USA). HFD/STZ-diabetic mice at 12 weeks of age received 20 μg/day PEG-ylated leptin (Protein Laboratories Rehovot Ltd., Rehovot, Israel) prepared in sterile water by daily i.p. injection while control HFD/STZ mice received water (vehicle).
8
Surgical Gonadectomy and Osmotic Pump Implantation in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Eight-week-old male and female mice underwent surgical gonadectomy as described above. During the procedure, animals were implanted with the Alzet 1004® micro-osmotic pump (DURECT Corporation, Cupertino, CA, USA). In female mice, pumps were implanted subcutaneously via the incision created during the ovariectomy. In male mice, a 1 cm, dorsal, longitudinal incision was made between the scapulae. To offset the position of the pump relative to the incision, a subcutaneous pocket was developed by blunt dissection lateral to the incision. All animals recovered for 5–7 days prior to the baseline ABR.
9
Evaluating AAV-αSyn Therapy with KYP-2047 and HUP-55
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Mice injected with AAV-αSyn received 10 mg/kg/day KYP-2047
(n = 10) orHUP-55 (n = 10) and vehicle (n = 10) treatment in minipumps
4 weeks after the virus vector surgeries. The dose was based on our
earlier studies with AAV2-CBAαSyn virus vector experiment with
mice,47 (link),57 (link) αSyn transgenic mice,22 (link) and on brain pharmacokinetic study with KYP-2047.46 (link) The treatment lasted for 4 weeks. AAV-GFP-injected
mice receivedHUP-55 treatment 10 mg/kg/day. Osmotic
minipump (Alzet 1004, Durect; flow rate of 0.11 μL/h) implanted
in the abdominal cavity was used to provide chronic administration.
Priming doses dissolved in 5% Tween 80 in saline (i.p., 10 mg/kg)
were given on the first day of the treatment to ensure the immediate
onset of the drug effect.
(n = 10) or
4 weeks after the virus vector surgeries. The dose was based on our
earlier studies with AAV2-CBAαSyn virus vector experiment with
mice,47 (link),57 (link) αSyn transgenic mice,22 (link) and on brain pharmacokinetic study with KYP-2047.46 (link) The treatment lasted for 4 weeks. AAV-GFP-injected
mice received
minipump (Alzet 1004, Durect; flow rate of 0.11 μL/h) implanted
in the abdominal cavity was used to provide chronic administration.
Priming doses dissolved in 5% Tween 80 in saline (i.p., 10 mg/kg)
were given on the first day of the treatment to ensure the immediate
onset of the drug effect.
10
Osmotic Minipump Implantation for Drug Delivery
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Osmotic minipump
(Alzet 1004, Durect; flow rate of 0.11 μL/h) implantation was
performed 4 weeks after virus vector injections in a stereotaxic operation
as described in the study by Svarcbahs et al.47 (link) Minipumps were filled with 16 mM KYP-2047 solution (0.2% dimethyl
sulfoxide (DMSO) in PBS) or 16 mMHUP-55 in 5% Tween
in saline (Braun) and primed according to producer’s instructions.
5% Tween in saline was used as a vehicle. A cannula (Alzet Brain Infusion
Kit 3, Durect) was implanted in the left hemisphere at 0.7 mm anterior
and 1.4 mm lateral to bregma as described in the study by Hof et al.,61 and was lowered 2.5 mm deep to lateral ventricle
(stereotaxic coordinates according to Franklin and Paxinos59 ) and the attached osmotic minipump was implanted
subcutaneously in the intracapsular region. Topical lidocaine (10
mg/mL), buprenorphine, (0.1 mg/kg) and carprofen (5 mg/kg) s.c. injections
were provided as pre- and postoperative pain management. Osmotic minipumps
were kept in mice for 28 days.
(Alzet 1004, Durect; flow rate of 0.11 μL/h) implantation was
performed 4 weeks after virus vector injections in a stereotaxic operation
as described in the study by Svarcbahs et al.47 (link) Minipumps were filled with 16 mM KYP-2047 solution (0.2% dimethyl
sulfoxide (DMSO) in PBS) or 16 mM
in saline (Braun) and primed according to producer’s instructions.
5% Tween in saline was used as a vehicle. A cannula (Alzet Brain Infusion
Kit 3, Durect) was implanted in the left hemisphere at 0.7 mm anterior
and 1.4 mm lateral to bregma as described in the study by Hof et al.,61 and was lowered 2.5 mm deep to lateral ventricle
(stereotaxic coordinates according to Franklin and Paxinos59 ) and the attached osmotic minipump was implanted
subcutaneously in the intracapsular region. Topical lidocaine (10
mg/mL), buprenorphine, (0.1 mg/kg) and carprofen (5 mg/kg) s.c. injections
were provided as pre- and postoperative pain management. Osmotic minipumps
were kept in mice for 28 days.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!